AN2 THERAPEUTICS INC (ANTX)

US0373261058 - Common Stock

3.28  -0.05 (-1.5%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

AN2 THERAPEUTICS INC

NASDAQ:ANTX (2/22/2024, 11:50:42 AM)

3.28

-0.05 (-1.5%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap97.55M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ANTX Daily chart

Company Profile

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The company is headquartered in Menlo Park, California and currently employs 35 full-time employees. The company went IPO on 2022-03-25. The firm is focused on developing treatments for rare, chronic and serious infectious diseases with high unmet needs. The Company’s initial product candidate is epetraborole, a once-daily, oral treatment for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic and progressive infectious disease caused by bacteria, mycobacteria. Epetraborole has antimycobacterial activity through the inhibition of an essential and universal step in bacterial protein synthesis. Its mechanism of action is enabled by boron chemistry, which is the Company’s core technology approach. Epetraborole is under development in a pivotal Phase II/III clinical trial as a once-daily, oral treatment for patients with NTM lung disease with an initial focus on treatment-refractory Mycobacterium avium complex (MAC) lung disease.

Company Info

AN2 THERAPEUTICS INC

1800 El Camino Real, Suite D

Menlo Park CALIFORNIA 90501

P: 16503319090

CEO: Robert Corrigan

Employees: 35

Website: https://www.an2therapeutics.com/

ANTX News

News Image7 days ago - Pomerantz LLPSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AN2 Therapeutics, Inc. ("AN2" or the "Company") (NASDAQ: ANTX). Such investors...

News Image9 days ago - ChartmillTuesday's session: top gainers and losers

Tuesday's session: top gainers and losers

News Image9 days ago - Seeking AlphaAN2 Therapeutics stock falls as Leerink cuts on trial setback

AN2 Therapeutics (ANTX) shares dropped as Leerink Partners downgraded the company after it paused enrollments in a clinical trial. Read more here.

News Image10 days ago - ChartmillThese stocks are moving in today's session

Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.

News Image10 days ago - ChartmillLet's take a look at the stocks that are in motion in today's session.

Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.

News Image10 days ago - Market News VideoOversold Conditions For AN2 Therapeutics (ANTX)

ANTX Twits

Here you can normally see the latest stock twits on ANTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example